Project Grant F31CA287604
Award Date
9/1/24
Completion Date
7/31/27
Dollars Obligated
$433K
Federal Agency
National Cancer Institute
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Durham, NC 27710, USA
Similar Awards
The Project Grant award R35CA293978, provided by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research), supports research to identify the mechanisms driving rapid evolution of cancer genomes. The $942,442 award to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA will fund investigations into two catastrophic mutational processes in cancer, chromothripsis and chromoplexy. The research aims to better understand the mechanisms of chromosome fragmentation, DNA...
The National Cancer Institute (NCI) awarded a $581,381 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Sloan-Kettering Institute for Cancer Research. The 5-year grant, effective June 5, 2025, will fund research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance in cancer. The key products of this research will be a better understanding of DNA damage repair pathways and how they contribute...
The National Cancer Institute (NCI) awarded a $238,722 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Sloan-Kettering Institute for Cancer Research in New York. The grant, awarded on August 18, 2025, will fund research to investigate the role of mutagenic DNA repair mechanisms, such as microhomology-mediated end joining (MMEJ), in driving acquired drug resistance in persister cancer cells. The research aims to define the specific mechanisms by which...
This federal Project Grant award of $125,619.00 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research by the Stowers Institute for Medical Research to investigate the relationship between natural variations in human centromeric DNA sequences and chromosome segregation accuracy. The research team is utilizing cutting-edge genomic, cytogenetic, and high-resolution microscopy techniques to map centromeric sequences and associated kinetochore...
This Project Grant award of $562,869, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), supports research to define the role of chromosome 17q gain in the malignancy of neuroblastoma, the most common pediatric extracranial solid tumor. The principal investigators at Children's Hospital Los Angeles will use a human stem cell model of neuroblastoma to: 1) compare the tumorigenic potential of 17q gain and MYCN in immature cells...
This Project Grant award from the National Cancer Institute (NCI), under the Federal Grant Program for Cancer Cause and Prevention Research (CFDA 93.393), supports research to elucidate the roles and regulatory mechanisms of the protein APE1 in the ATR DNA damage response signaling pathway. The $342,569 award, effective March 1, 2025 through February 28, 2030, will enable researchers at the University of North Carolina at Charlotte to investigate how APE1 forms liquid-liquid phase separations in...
This $312,892 Project Grant, awarded by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program, supports research at Duke University to investigate the role of type 3 innate lymphoid cells (ILC3s) in regulating the melanoma tumor microenvironment. The goal is to better understand how ILC3s and their secretion of interleukin-17 (IL-17) can create an immunosuppressive environment that hinders the effectiveness of immune checkpoint inhibitor (ICI) therapy for...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) federal grant program, provides $223,176 to Duke University to investigate the role of SMARCAL1 depletion in promoting increased immunogenicity in alternative lengthening of telomeres (ALT)+ high-grade gliomas (HGGs). The overarching goal is to study how therapeutic targeting of SMARCAL1 can lead to tumor-specific DNA damage and inflammation, potentially overcoming the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $170,640 in funding to the Dana-Farber Cancer Institute, Inc. (DFCI) from July 1, 2025 to June 30, 2027. The grant supports research to investigate the role of histone cleavage in breast cancer, specifically focusing on how the KDM4C histone demethylase drives tumor growth by preventing proteolytic cleavage of the histone H3 N-terminal tail by cathepsin L. The research aims to...
The National Cancer Institute (NCI) awarded a $417,586 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Broad Institute, Inc. to develop a "Platform for Multi-Modal Single Nucleus Spatial Genomics for Molecular Tumor Analysis." This 3-year project, commencing on August 1, 2024, aims to extend the institute's "Slide-Tags" single-cell spatial genomics technology to enable comprehensive profiling of human tumor samples. The project will integrate molecular, cellular,...